SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Antex Biologics (ANTX)
ANTX 1.080-0.9%Dec 30 3:55 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Amigo Mike who wrote (1145)1/29/1999 8:42:00 AM
From: John R Resseger  Read Replies (1) of 1476
 
Mike.

In regards to phase 2 trials on Campy, I asked MS Stevens what we were waiting for and whether the results so far were conclusive that it works. She refered me to this on the web site.

Antex's Campylobacter vaccine consists of inactivated bacterial cells produced by the Company's newly patented Nutriment Signal Transduction (NST) technology. NST is the ex vivo simulation of the in vivo environment to produce bacterial vaccines that are identical to the infectious bacteria causing disease in humans, mimicking bacterial virulence activity. Preclinical studies by Antex have shown that the NST-produced bacterial cell vaccine provides a strong immunological response, as indicated by antibody and cytokine production, and is 100 percent effective at protecting against infection and disease.

She went on to say that the concluded phase 2 testing in humans showed what adjustment had to be maid to improve the effectiveness in humans.

Due to low pay and moral in the Navy, I think they'll have to use Senators and White House special assistants for the next phase.

The Navy is still rummaging through the data searching for the unexpected.

When they are done ANTEX will figure out what adjustments to make and proceed to phase 3
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News